Amlodipine in Pregnancy: Safety Profile, Risks, and Clinical Guidance
Amlodipine (a dihydropyridine calcium channel blocker) is not a first-line antihypertensive in pregnancy, but may be used when preferred agents are unsuitable.
Pregnancy Category & Evidence
- FDA: Category C (animal fetal risk, no adequate human studies).
- ACOG/NHBPEP preferred agents: Methyldopa, labetalol, nifedipine XL. Amlodipine is an alternative.
- Human data: Registries and cohort studies (thousands of exposures) show no clear pattern of major malformations. Some signal for congenital heart defects (VSD, ASD) and intrauterine growth restriction (IUGR)—confounded by hypertension itself.
- Placental transfer: Yes (lipophilic).
- Breastfeeding: Low milk levels; considered compatible (AAP).
Clinical Decision Framework
- If already on amlodipine + well-controlled → often continued (switching risks destabilization).
- New onset HTN in pregnancy → start preferred agent (labetalol, nifedipine XL, methyldopa).
- Severe HTN (≥160/110) → IV labetalol/hydralazine/nifedipine PO; amlodipine not acute.
- Monitor: BP, fetal growth (serial US), maternal edema, renal function.
Key Counseling Points
- Uncontrolled hypertension poses greater fetal risk (abruption, IUGR, stillbirth, preeclampsia) than most antihypertensives.
- Do not stop abruptly—rebound hypertension.
- Report edema, headache, visual changes, epigastric pain (preeclampsia signs).
Shared decision-making with OB/MFM is essential.
Pregnancy & Health - Related Articles
- Pineapple and Pregnancy: What the Research Says
- Chorionic Villus Sampling (CVS) for CMT Testing: Timing & Procedure
- Pregnancy Nutrition: 11 Foods to Avoid or Limit for a Healthy Pregnancy
- Pregnancy Symptoms After Salpingectomy: What They Really Mean
- Blood Pregnancy Tests: Accuracy, Availability, and How They Work
- Respiratory MRSA in Pregnancy: Risks to the Fetus
- Three-Week Period: Causes, Evaluation, and When to See a Doctor
